Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4213246
Max Phase: Preclinical
Molecular Formula: C20H16N4O3
Molecular Weight: 360.37
Molecule Type: Small molecule
Associated Items:
ID: ALA4213246
Max Phase: Preclinical
Molecular Formula: C20H16N4O3
Molecular Weight: 360.37
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CNC(=O)c1cc(Oc2ccc3cc(-c4noc(C)n4)ccc3c2)ccn1
Standard InChI: InChI=1S/C20H16N4O3/c1-12-23-19(24-27-12)15-4-3-14-10-16(6-5-13(14)9-15)26-17-7-8-22-18(11-17)20(25)21-2/h3-11H,1-2H3,(H,21,25)
Standard InChI Key: RRRSAURDWVMSJV-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 360.37 | Molecular Weight (Monoisotopic): 360.1222 | AlogP: 3.75 | #Rotatable Bonds: 4 |
Polar Surface Area: 90.14 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 14.00 | CX Basic pKa: 3.03 | CX LogP: 2.98 | CX LogD: 2.98 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.60 | Np Likeness Score: -1.29 |
1. Kim J, Shin JS, Ahn S, Han SB, Jung YS.. (2018) 3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus., 9 (7): [PMID:30034598] [10.1021/acsmedchemlett.8b00134] |
Source(1):